Avacta Group (LSE:AVCT) Change In Receivables : £0.84 Mil (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Change In Receivables?

Avacta Group's change in receivables for the quarter that ended in Dec. 2023 was £0.70 Mil. It means Avacta Group's Accounts Receivable declined by £0.70 Mil from Jun. 2023 to Dec. 2023 .

Avacta Group's change in receivables for the fiscal year that ended in Dec. 2023 was £0.84 Mil. It means Avacta Group's Accounts Receivable declined by £0.84 Mil from Dec. 2022 to Dec. 2023 .

Avacta Group's Accounts Receivable for the quarter that ended in Dec. 2023 was £3.25 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Avacta Group's Days Sales Outstanding for the six months ended in Dec. 2023 was 52.14.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Avacta Group's liquidation value for the six months ended in Dec. 2023 was £-31.03 Mil.

Avacta Group Change In Receivables Historical Data

The historical data trend for Avacta Group's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Change In Receivables Chart

Avacta Group Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.01

-0.81

-1.60

2.23

0.84

Avacta Group Semi-Annual Data
	Jul13	Jan14	Jul14	Jan15	Jul15	Jan16	Jul16	Jan17	Jul17	Jan18	Jul18	Jan19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															1.29	-0.95	3.18	0.14	0.70

Avacta Group Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.84 Mil.

Avacta Group (LSE:AVCT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Avacta Group's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3.245	/	11.358	*	91
=	52.14

2. In Ben Graham's calculation of liquidation value, Avacta Group's accounts receivable are only considered to be worth 75% of book value:

Avacta Group's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	16.627	-	51.386	+	0.75 * 3.245	+	0.5 * 2.585
=	-31.03

Avacta Group Change In Receivables Related Terms

Thank you for viewing the detailed overview of Avacta Group's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Avacta Group (LSE:AVCT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

AVCTF:USA RTQ1:Germany

Address

Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA

Website

https://www.avacta.com

Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines